居家抗阻与力量训练方案对高海拔慢性阻塞性肺疾病患者HIF-1α表达影响的临床试验方案
该临床试验采用准实验设计、纵向重复测量,在4个时间点比较组内与组间差异,纳入居住于海拔2600米以上、无肿瘤、肾脏、心脏或肌肉骨骼合并症且体力活动水平低的慢阻肺患者,实施为期8周的居家抗阻与肌肉力量训练(8-WVP),主要结局为HIF-1α、VEGF和EPO表达,次要结局包括肺功能、运动表现和血液学指标。
要点
- 研究纳入居住于海拔2600米以上、体力活动水平低的慢阻肺患者。
- 干预为为期8周的居家抗阻与肌肉力量训练方案(8-WVP)。
- 主要结局为HIF-1α、VEGF和EPO表达,在4个时间点测量。
核心结论
- 该临床试验方案旨在促进对高海拔慢阻肺患者运动后缺氧适应相关信号蛋白表达的认识。
- 作者认为该人群目前缺乏相关数据,所生成知识将增进对疾病病理生理的理解并影响未来基于运动处方的医疗与治疗决策。
研究设计与样本
- 准实验设计,纵向重复测量分析,含组内与组间比较,在4个时间点测量主要和次要变量。
- 纳入诊断为慢阻肺且居住于高海拔(>2600米)者。
- 纳入标准为无肿瘤、肾脏、心脏或肌肉骨骼合并症且体力活动水平低。
- 干预为为期8周的居家抗阻与肌肉力量训练方案(8-WVP)。
- 主要结局变量为HIF-1α、VEGF和EPO表达。
关键数值与推荐
- 主要结局变量为HIF-1α、VEGF和EPO表达。
- 次要结局变量包括肺功能(肺量计测定)、运动表现(运动心肺功能测试和测力计测定)及血液学参数。
- 干预为为期8周的居家抗阻与肌肉力量训练方案(8-WVP)。
- 研究在4个时间点测量主要和次要变量。
- 试验注册号为NCT04955977,首次发布2021年7月9日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is a chronic, noncommunicable disease characterized by hypoxemia, with altered lung function, dyspnea on mild exertion, limited tolerance to physical exertion, and functional impairment. Physical exercise has been recommended worldwide as an efficient strategy to improve the autonomy and quality of life of patients affected by COPD. However, the adaptive molecular mechanisms occurring in these patients after the exposure to the hypoxic stimulus triggered by physical exercise have currently not been described in populations living at high altitude. METHODS: The clinical trial we are presenting here consists of a quasi-experimental design with longitudinal analysis of repeated measures, with intra- and inter-group comparisons, measuring primary and secondary variables in 4 temporal points. Participants will be people with a diagnosis of COPD residing at high altitudes (> 2600 m), without oncological, renal, cardiac, or musculoskeletal comorbidities with a low level of physical activity. The intervention will be an 8-week program of physical exercise of resistance and muscular strength (8-WVP) which will be carried out at home. Primary outcome variables will be the expression of HIF-1α, VEGF, and EPO. As secondary outcome variables, we will consider lung function (measured by spirometry), physical performance (measured by ergospirometry and dynamometry), and hematological parameters. DISCUSSION: The results obtained after the clinical trial proposed here will promote knowledge on the expression of signaling proteins as an adaptive response to hypoxia in people with COPD living at high altitude, which will be relevant because there are not data on this population group. The knowledge generated from the application of this protocol will increase the pathophysiological understanding of the disease and future medical and therapeutic decision-making based on physical exercise prescription. TRIAL REGISTRATION {2A}: NCT04955977 [ClinicalTrials.gov]-NCT04955977 [WHO ICRTP]. First Posted: July 9, 2021.
引用
- Villamil-Parra W, Cristancho-Mejía É, Ramon Torrella J, et al. Effects of a physical exercise program on HIF-1α in people with Chronic Obstructive Pulmonary Disease living at high altitude: study protocol for a clinical trial. Trials. 2023. PMID: 37899477. doi:10.1186/s13063-023-07698-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。